Journal article
Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)
Abstract
Abstract
Background Trametinib (Mekinist ®) is an oral bioavailable MEK 1/2 inhibitor that is FDA approved in combination with BRAF inhibitor Dabrafenib for BRAFV600 mutant solid tumors. The single agent recommended phase 2 dose (RP2D) is 2 mg daily (QD). No clinical data is available on recommendation of trametinib dosing in various degrees of hepatic dysfunction (HD). This study was designed to evaluate RP2D, maximum …
Authors
Voon PJ; Chen EX; Chen HX; Lockhart AC; Sahebjam S; Kelly K; Vaishampayan UN; Subbiah V; Razak AR; Renouf DJ
Journal
Molecular Cancer Therapeutics, Vol. 20, No. 12_Supplement, pp. p035–p035
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 1, 2021
DOI
10.1158/1535-7163.targ-21-p035
ISSN
1535-7163